S1 Table. List of 96 Autoimmune Diseases 1

Total Page：16

File Type：pdf, Size：1020Kb

S1 Table. List of 96 autoimmune diseases 1. Acantholysis 33. Erythematous pemphigus 65. Mucous membrane pemphigoid 2. Acute disseminated encephalomyelitis 34. Experimental autoimmune disease 66. Myasthenia gravis 3. Addison Disease 35. Felty syndrome 67. Nervous system autoimmune disease, experimental 4. Adult onset Still disease 36. Giant cell arteritis 68. Nonarticular rheumatism 5. Allergic glomerulonephritis 37. Glomerulonephritis, IgA 69. Ophthalmia, sympathetic 6. ANCA associated vasculitis 38. Glomerulonephritis, membranous 70. Opsoclonus myoclonus syndrome 7. Anemia, hemolytic, autoimmune 39. Goodpasture syndrome 71. Paraneoplastic pemphigus 8. Ankylosing spondylitis 40. Granulomatosis with polyangiitis 72. Pemphigoid 9. Anti-glomerular basement membrane disease 41. Graves disease 73. Pemphigoid gestationis 10. Anti-N-methyl-D-aspartate receptor encephalitis 42. Graves ophthalmopathy 74. Pemphigus 11. Antiphospholipid syndrome 43. Guillain Barre syndrome 75. Pemphigus foliaceus 12. Antisynthetase syndrome 44. Hailey Hailey disease 76. Pemphigus vulgaris 13. Autoimmune diseases of the nervous system 45. Hashimoto disease 77. Pernicious anemia 14. Autoimmune gastritis 46. Heparin induced thrombocytopenia 78. Polyendocrinopathies, autoimmune 15. Autoimmune hypophysitis 47. Hepatitis, autoimmune 79. Polyradiculoneuropathy 16. Autoimmune liver disease 48. Idiopathic hypoparathyroidism 80. Postpartum thyroiditis 17. Autoimmune lung disease 49. Idiopathic thrombocytopenic purpura 81. Primary biliary cirrhosis 18. Autoimmune lymphoproliferative syndrome 50. IgA pemphigus 82. Rheumatic disease 19. Autoimmune pancreatitis 51. Immune complex nephritis 83. Rheumatic heart disease 20. Autoimmune polyendocrinopathy candidiasis 52. Immunoglobulin A nephropathy 84. Rheumatic polymyalgia ectodermal dystrophy 53. Juvenile rheumatoid arthritis 85. Rheumatoid arthritis 21. Autoimmune skin disease 54. Lambert-Eaton myasthenic syndrome 86. Rheumatoid nodule 22. Autoimmune thyroiditis 55. Latent autoimmune diabetes in adults 87. Rheumatoid vasculitis 23. Autoimmune uveitis 56. Leukocytoclastic vasculitis 88. Scleroderma 24. Behçet disease 57. Limited scleroderma 89. Sjogren syndrome 25. Bullous pemphigoid 58. Linear IgA bullous dermatosis 90. Stiff-Person syndrome 26. Celiac disease 59. Linear scleroderma 91. Syndrome CREST 27. Churg Strauss syndrome 60. Localized scleroderma 92. Systemic juvenile idiopathic arthritis 28. Demyelinating autoimmune diseases, central 61. Lupus nephritis 93. Systemic lupus erythematosus nervous system 62. Lupus vasculitis, central nervous system 94. Systemic sclerosis 29. Dermatitis herpetiformis 63. Microscopic polyangiitis 95. Uveomeningoencephalitic syndrome 30. Diabetes mellitus, type 1 64. Morphea 96. Vasculitis, central nervous system 31. Diffuse scleroderma 32. Endocrine ophthalmopathy .

Copy Link

Recommended publications

82858686.Pdf
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector MINI REVIEW published: 23 March 2017 doi: 10.3389/fimmu.2017.00336 Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic inflammatory Central Nervous System Disorders Robert Weissert* Department of Neurology, Neuroimmunology, University of Regensburg, Regensburg, Germany There are common aspects and mechanisms between different types of autoimmune diseases such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSDs), and autoimmune encephalitis (AE) as well as paraneoplastic inflammatory disorders of the central nervous system. To our present knowledge, depending on the disease, T and B cells as well as antibodies contribute to various aspects of the pathogenesis. Possibly the events leading to the breaking of tolerance between the different diseases are of great similarity and so far, only partially understood. Beside Edited by: endogenous factors (genetics, genomics, epigenetics, malignancy) also exogenous fac- Björn Tackenberg, tors (vitamin D, sun light exposure, smoking, gut microbiome, viral infections) contribute Philipps University of Marburg, Germany to susceptibility in such diseases. What differs between these disorders are the target Reviewed by: molecules of the immune attack. For T cells, these target molecules are presented on Anne Kathrin Mausberg, major histocompatibility complex (MHC) molecules as MHC-bound ligands. B cells have Essen University Hospital, Germany Pavan Bhargava, an important role by amplifying the immune response of T cells by capturing antigen with Johns Hopkins School of Medicine, their surface immunoglobulin and presenting it to T cells. Antibodies secreted by plasma USA cells that have differentiated from B cells are highly structure specific and can have *Correspondence: important effector functions leading to functional impairment or/and lesion evolvement.
[Show full text]
ON the VIRUS ETIOLOGY of PEMIPHIGUS and DERMATITIS HERPETIFORMIS DUHRING*, Tt A.MARCHIONINI, M.D
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ON THE VIRUS ETIOLOGY OF PEMIPHIGUS AND DERMATITIS HERPETIFORMIS DUHRING*, tt A.MARCHIONINI, M.D. AND TH. NASEMANN, M.D. The etiology of pemphigus and dermatitis herpetiformis (Duhring) is, as Lever (33) has pointed ont in his recently published monograph (1953), still unknown, despite many clinical investigations and despite much bacteriologic and virus research using older and newer methods. There can be no doubt that the number of virus diseases has increased since modern scientific, (ultrafiltra- tion, ultracentrifuge, electron-microscope, etc.) and newer biological methods (chorionallantois-vaccination, special serological methods, tissue cultures, etc.) have been used on a larger scale in clinical research. Evidence of virus etiology, however, is not always conclusive. What is generally the basis for the assumption of the virus nature of a disease? First of all, we assume on the basis of epidemiology and clinical observations that the disease is iufectious and that we are dealing with a disease of a special character (morbus sui qeneris). Furthermore, it must be ruled out that bacteria, protozoa and other non-virus agents are responsible for the disease. This can be done by transfer tests with bacteria-free ultrafiltrates. If these are successful, final prcof of the virus etiology has to be established by isolation of the causative agent and its cultivation in a favorable host-organism through numerous transfers. Let us look now from this point of view at pemphigus and dermatitis herpetiformis (Duhring). We are not dealing here with the old controversy, whether both diseases are caused by the same virus (unitarian theory) or by two different viruses (dualistic theory) or are due to two variants of different virulence of the same virus (Duhring-virus-attenu- ated form).
[Show full text]
Immune Globulin Therapy
Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 02/01/2013 Section: Prescription Drugs Place(s) of Service: Outpatient I. Description Intravenous immune globulin (IVIG) is a sterile, highly purified preparation of unmodified immunoglobulins, which are isolated from large pools of human plasma. IVIG is an infusion used to treat patients with inherited or acquired immune deficiencies. It provides passive immunity against infection by increasing a person’s antibody titer and antigen-antibody reaction potential. IVIG supplies a broad spectrum of IgG antibodies against bacterial, viral, parasitic, and mycoplasmal antigens. Subcutaneous immune globulin (Sub-q IG) is FDA approved for the treatment of patients with primary immune deficiency. It is injected under the skin using an infusion pump, which means patients can self-administer the product in a home setting. II. Criteria/Guidelines A. IVIG therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following indications: 1. Treatment of primary immunodeficiencies, including: a. Congenital agammaglobulinemia ( X-linked agammaglobulinemia) b. Hypogammaglobulinemia c. Common variable immunodeficiency d. X-linked immunodeficiency with hyperimmunoglobulin M e. Severe combined immunodeficiency f. Wiskott-Aldrich syndrome 2. Idiopathic thrombocytopenic purpura (ITP) Immune Globulin Therapy 2 3. Prevention of graft-versus-host disease in non-autologous bone marrow transplant patients age 20 or older in the first 100 days after transplantation 4. Kawasaki syndrome when used in conjunction with aspirin 5. Prevention of infection in: a. HIV-infected pediatric patients b. Bone marrow transplant patients age 20 or older in the first 100 days after transplantation c.
[Show full text]
Goodpasture Syndrome
orphananesthesia Anaesthesia recommendations for Goodpasture syndrome Disease name: Goodpasture syndrome ICD 10: M31.0 Synonyms: Goodpasture’s syndrome (GS), anti-glomerular basement membrane disease, crescentic glomerulonephritis type 1, GPS Disease summary: Goodpasture syndrome is a rare and organ-specific autoimmune disease (Gell and Coombs classification type II). It is mediated by anti-glomerular basement membrane (anti-GBM) antibodies [7]. The disease was first described by Dr. Ernest Goodpasture in 1919 [6], whereby the glomerular basement membrane was first identified as antigen in 1950s. More than one decade later, researchers succeeded in defining the association between antibodies taken from diseased kidneys and nephritis [7]. The disorder is characterised by autoantibodies targeting at the NC1-domain of the α3 chain of type IV collagen in the glomerular and alveolar basement membrane with activation of the complement cascade among other things [7,17]. The exclusive location of this α3 subunit in basement membranes only in lung and kidney is responsible for the unique affection of these two organs in GPS [7]. Nevertheless, the aetiology and the triggering stimuli for anti-GBM production remain unknown. Due to the fact that patients with specific human leukocyte antigen (HLA) types are more susceptible, a genetic predisposition HLA-associated seems possible [4,7]. However, because this strongly associated allele is frequently present, there seem to be additional behavioural or environmental factors influencing immune response and disease expression. The latter may include respiratory infections (e.g., influenza A2), exposition to hydrocarbon fumes, organic solvents, metallic dust, tobacco smoke, certain drugs (i.e., rifampicin, allopurinol, cocaine), physical damage to basement membrane (e.g., lithotripsy or membranous glomerulonephritis) as well as lymphocyte-depletion therapy (such as alemtuzumab), but unequivocal evidence is lacking [4,7,9,17].
[Show full text]
Goodpasture's Syndrome: an Analysis of 29 Cases
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 13 (1978), pp. 492—504 Goodpasture's syndrome: An analysis of 29 cases CLINTON A. TEAGUE, PETER B. DOAK, IAN J. SIMPSON, STEPHEN P. RAINER, and PETER B. HERDSON The Departments of Pathology and Medicine, University of Auckland School of Medicine, Auckland, New Zealand Goodpasture's syndrome: An analysis of 29 cases. The patho- ation between lung hemorrhage and glomeruloneph- logic features of 29 cases of Goodpasture's syndrome occurring during a 13-yr period in Auckland have been reviewed and corre- ntis classically affecting young men. They referred to lated with clinical findings. There were 20 males and nine females such a patient reported about 40 years previously by in the series; two of the males and three of the females were Goodpasture [2]. During the past two decades, a Maoris. Age at the time of onset of symptoms ranged from 17 to 75 great deal has been learned about the immunological yr, with about 76% of the patients being from 17 to 27 yr of age. Sixteen (55%) of the patients died from less than a week up to aspects of several forms of glomerulonephritis, in- about two years following the onset of symptoms, and the remain- cluding the anti-glomerular basement membrane ing 13 are alive from 30 weeks to 14 yr after initial presentation. (anti-GBM) type of disease with cross-reactivity be- Underlying renal disease varied from mild focal glomerulitis to end-stage glomerulonephritis by light microscopy, but characteris- tween lung and kidney which is a feature of Good- tic glomerular changes were seen in all specimens examined by pasture's syndrome [3].
[Show full text]
Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002
Department of Health & Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002 CHANGE REQUEST 2149 HEADER SECTION NUMBERS PAGES TO INSERT PAGES TO DELETE Table of Contents 2 1 45-30 - 45-31 2 2 NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2002 IMPLEMENTATION DATE: October 1, 2002 Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of Autoimmune Mucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Use J1563 to bill for IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid, and (5) Epidermolysis Bullosa Acquisita. This revision to the Coverage Issues Manual is a national coverage decision (NCD). The NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869(f)(1)(A)(i) of the Social Security Act.) These instructions should be implemented within your current operating budget. DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted. CMS-Pub.
[Show full text]
A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary ORIGINAL RESEARCH Adenoma Preoperatively
A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary ORIGINAL RESEARCH Adenoma Preoperatively A. Gutenberg BACKGROUND AND PURPOSE: Autoimmune hypophysitis (AH) mimics the more common nonsecret- J. Larsen ing pituitary adenomas and can be diagnosed with certainty only histologically. Approximately 40% of patients with AH are still misdiagnosed as having pituitary macroadenoma and undergo unnecessary I. Lupi surgery. MR imaging is currently the best noninvasive diagnostic tool to differentiate AH from V. Rohde nonsecreting adenomas, though no single radiologic sign is diagnostically accurate. The purpose of this P. Caturegli study was to develop a scoring system that summarizes numerous MR imaging signs to increase the probability of diagnosing AH before surgery. MATERIALS AND METHODS: This was a case-control study of 402 patients, which compared the presurgical pituitary MR imaging features of patients with nonsecreting pituitary adenoma and controls with AH. MR images were compared on the basis of 16 morphologic features besides sex, age, and relation to pregnancy. RESULTS: Only 2 of the 19 proposed features tested lacked prognostic value. When the other 17 predictors were analyzed jointly in a multiple logistic regression model, 8 (relation to pregnancy, pituitary mass volume and symmetry, signal intensity and signal intensity homogeneity after gadolin- ium administration, posterior pituitary bright spot presence, stalk size, and mucosal swelling) remained significant predictors of a correct classification. The diagnostic score had a global performance of 0.9917 and correctly classified 97% of the patients, with a sensitivity of 92%, a specificity of 99%, a positive predictive value of 97%, and a negative predictive value of 97% for the diagnosis of AH.
[Show full text]
Interstitial Granuloma Annulare Triggered by Lyme Disease
Volume 27 Number 5| May 2021 Dermatology Online Journal || Case Presentation 27(5):11 Interstitial granuloma annulare triggered by Lyme disease Jordan Hyde1 MD, Jose A Plaza1,2 MD, Jessica Kaffenberger1 MD Affiliations: 1Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA, 2Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA Corresponding Author: Jessica Kaffenberger MD, Division of Dermatology, The Ohio State University Medical Wexner Medical Center, Suite 240, 540 Officenter Place, Columbus, OH 43230, Tel: 614-293-1707, Email: [email protected] been associated with a variety of systemic diseases Abstract including diabetes mellitus, malignancy, thyroid Granuloma annulare is a non-infectious disease, dyslipidemia, and infection [3,4]. granulomatous skin condition with multiple different associations. We present a case of a man in his 60s There are multiple histological variants of GA, with a three-week history of progressive targetoid including interstitial GA. The histopathology of plaques on his arms, legs, and trunk. Skin biopsy classic GA demonstrates a focal degeneration of demonstrated interstitial granuloma annulare. collagen surrounded by an inflammatory infiltrate Additional testing revealed IgM antibodies to Borrelia composed of lymphocytes and histiocytes. In a less burgdorferi on western blot suggesting interstitial common variant, interstitial GA, scattered histiocytes granuloma annulare was precipitated by the recent are seen
[Show full text]
2017 Oregon Dental Conference® Course Handout
2017 Oregon Dental Conference® Course Handout Nasser Said-Al-Naief, DDS, MS Course 8125: “The Mouth as The Body’s Mirror: Oral, Maxillofacial, and Head and Neck Manifestations of Systemic Disease” Thursday, April 6 2 pm - 3:30 pm 2/28/2017 The Mouth as The Body’s Mirror Oral Maxillofacial and Head and Neck Manifestation of Ulcerative Conditions of Allergic & Immunological Systemic Disease the Oro-Maxillofacial Diseases Region Nasser Said-Al-Naief, DDS, MS Professor & Chair, Oral Pathology and Radiology Director, OMFP Laboratory Oral manifestations of Office 503-494-8904// Direct: 503-494-0041 systemic diseases Oral Manifestations of Fax: 503-494-8905 Dermatological Diseases Cell: 1-205-215-5699 Common Oral [email protected] Conditions [email protected] OHSU School of Dentistry OHSU School of Medicine 2730 SW Moody Ave, CLSB 5N008 Portland, Oregon 97201 Recurrent aphthous stomatitis (RAS) Recurrent aphthous stomatitis (RAS) • Aphthous" comes from the Greek word "aphtha”- • Recurrence of one or more painful oral ulcers, in periods of days months. = ulcer • Usually begins in childhood or adolescence, • The most common oral mucosal disease in North • May decrease in frequency and severity by age America. (30+). • Affect 5% to 66% of the North American • Ulcers are confined to the lining (non-keratinized) population. mucosa: • * 60% of those affected are members of the • Buccal/labial mucosa, lateral/ventral tongue/floor of professional class. the mouth, soft palate/oropharyngeal mucosa • Etiopathogenesis: 1 2/28/2017 Etiology of RAU Recurrent Aphthous Stomatitis (RAS): Types: Minor; small size, shallow, regular, preceeded by prodrome, heal in 7-10 days Bacteria ( S.
[Show full text]
ANCA--Associated Small-Vessel Vasculitis
ANCA–Associated Small-Vessel Vasculitis ISHAK A. MANSI, M.D., PH.D., ADRIANA OPRAN, M.D., and FRED ROSNER, M.D. Mount Sinai Services at Queens Hospital Center, Jamaica, New York and the Mount Sinai School of Medicine, New York, New York Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis is the most common primary sys- temic small-vessel vasculitis to occur in adults. Although the etiology is not always known, the inci- dence of vasculitis is increasing, and the diagnosis and management of patients may be challenging because of its relative infrequency, changing nomenclature, and variability of clinical expression. Advances in clinical management have been achieved during the past few years, and many ongoing studies are pending. Vasculitis may affect the large, medium, or small blood vessels. Small-vessel vas- culitis may be further classified as ANCA-associated or non-ANCA–associated vasculitis. ANCA–asso- ciated small-vessel vasculitis includes microscopic polyangiitis, Wegener’s granulomatosis, Churg- Strauss syndrome, and drug-induced vasculitis. Better definition criteria and advancement in the technologies make these diagnoses increasingly common. Features that may aid in defining the spe- cific type of vasculitic disorder include the type of organ involvement, presence and type of ANCA (myeloperoxidase–ANCA or proteinase 3–ANCA), presence of serum cryoglobulins, and the presence of evidence for granulomatous inflammation. Family physicians should be familiar with this group of vasculitic disorders to reach a prompt diagnosis and initiate treatment to prevent end-organ dam- age. Treatment usually includes corticosteroid and immunosuppressive therapy. (Am Fam Physician 2002;65:1615-20. Copyright© 2002 American Academy of Family Physicians.) asculitis is a process caused These antibodies can be detected with indi- by inflammation of blood rect immunofluorescence microscopy.
[Show full text]
Bullous Pemphigoid: Trigger and Predisposing Factors
biomolecules Review Bullous Pemphigoid: Trigger and Predisposing Factors , , Francesco Moro * y , Luca Fania * y, Jo Linda Maria Sinagra, Adele Salemme and Giovanni Di Zenzo First Dermatology Clinic, IDI-IRCCS, Via Dei Monti di Creta 104, 00167 Rome, Italy; [email protected] (J.L.M.S.); [email protected] (A.S.); [email protected] (G.D.Z.) * Correspondence: [email protected] (F.M.); [email protected] (L.F.); Tel.: +39-(342)-802-0004 (F.M.) These authors have equally contributed to the manuscript. y Received: 7 September 2020; Accepted: 8 October 2020; Published: 10 October 2020 Abstract: Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and BP230. Its pathogenesis depends on the interaction between predisposing factors, such as human leukocyte antigen (HLA) genes, comorbidities, aging, and trigger factors. Several trigger factors, such as drugs, thermal or electrical burns, surgical procedures, trauma, ultraviolet irradiation, radiotherapy, chemical preparations, transplants, and infections may induce or exacerbate BP disease. Identiﬁcation of predisposing and trigger factors can increase the understanding of BP pathogenesis. Furthermore, an accurate anamnesis focused on the recognition of a possible trigger factor can improve prognosis by promptly removing it. Keywords: bullous pemphigoid; autoimmune bullous disease; trigger factors; predisposing factors; etiopathogenesis 1. Introduction Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, aﬀecting predominantly elderly people. It is characterized by generalized pruritic urticarial plaques and tense subepithelial blisters. BP autoantibodies are directed mainly against two hemidesmosomal proteins, BP180 (also termed type XVII collagen) and BP230, which are components of the dermo-epidermal junction (DEJ) [1].
[Show full text]
Bullous Pemphigoid/Pemphigus and Administration of the Pfizer/Biontech Vaccine (Comirnaty®). Introduction the Pfizer/Bionte
Bullous Pemphigoid/Pemphigus and administration of the Pfizer/BioNTech vaccine (Comirnaty®). Introduction The Pfizer/BioNTech vaccine (Comirnaty®) is a COVID-19-mRNA-vaccine (nucleoside modified). It is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. [1] The nucleoside-modified messenger RNA in Comirnaty® is formulated in lipid nanoparticles, which enable delivery of the nonreplicating RNA into host cells to direct transient expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length Spike glycoprotein with two point mutations within the central helix. [1] Comirnaty® has been registered in Europe since December 21st, 2020. Bullous skin diseases are a group of dermatoses characterized by blisters and bullae in the skin and mucous membranes. The most common are pemphigus and bullous pemphigoid (BP). Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin diseases. In pemphigus, keratinocytes in epidermis and mucous membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the basement membrane. Bullous pemphigoid is a more common disease than pemphigus [2]. Bullous pemphigoid is the most common heterogeneous subepidermal autoimmune blistering disease (incidence 7 per million person year) [3,4], with an increasing prevalence after the age of 70, although it can also occur in the younger. It is characterized by auto-antibodies against different structural proteins of the hemidesmosomes in the epidermal basement membrane zone (EBMZ). Bullous pemphigoid typically causes severe pruritus with predominantly cutaneous lesions consisting of tense (fluid filled) bullae, erythema, and urticarial plaques.
[Show full text]